Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925859 · ClinicalTrials.gov registry record · Phase 1
EryDex Pharmacokinetics in Healthy Volunteers
A Phase 1 study of Healthy, sponsored by Quince Therapeutics S.p.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01925859: Completed Phase 1 study of Healthy, sponsored by Quince Therapeutics S.p.A..
NCT01925859 is a Phase 1 study of Healthy that has completed, run by Quince Therapeutics S.p.A.. The registered enrollment target is 18 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01925859, a Phase 1 study of Healthy, has completed, sponsored by Quince Therapeutics S.p.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the pharmacokinetic properties of two different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.
Conditions Studied
Interventions
- DRUG EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925859
The ClinicalTrials.gov registry entry for NCT01925859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is Quince Therapeutics S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which EryDex (dexamethasone sodium phosphate encapsulated erythrocytes) is the first listed.
NCT01925859 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01925859 about?
NCT01925859 is a clinical study titled "EryDex Pharmacokinetics in Healthy Volunteers". To compare the pharmacokinetic properties of two different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.
What is the current status of trial NCT01925859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-06. Estimated completion is 2013-10.
What conditions does trial NCT01925859 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01925859?
The interventions under investigation include: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes) (DRUG).
Who is sponsoring clinical trial NCT01925859?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01925859 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.